Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA

Kenan Zhang; Xing Liu; Guanzhang Li; Xin Chang; Shouwei Li; Jing Chen; Zheng Zhao; Jiguang Wang; Tao Jiang; Ruichao Chai

doi:10.20892/j.issn.2095-3941.2022.0469

Article Information

vol. 19 no. 10 1460-1476

DOI

https://doi.org/10.20892/j.issn.2095-3941.2022.0469

Published By

Cancer Biology & Medicine

History

Received August 5, 2022
Accepted September 5, 2022
Published online November 3, 2022.

Copyright: © 2022, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

Kenan Zhang1,
Xing Liu2,
Guanzhang Li1,3,
Xin Chang4,
Shouwei Li4,
Jing Chen1,
Zheng Zhao1,
Jiguang Wang5,6,7,
Tao Jiang1,3 ⇑ and
Ruichao Chai1,2,5 ⇑

¹Department of Molecular Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China
²Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China
³Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
⁴Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China
⁵Division of Life Science and State Key Laboratory of Molecular Neuroscience, Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR 999077, China
⁶Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong SAR 999077, China
⁷HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute, Futian, Shenzhen 518057, China